MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos 10.3892/mco.2017.1505 MCO-0-0-1505 Articles A phase I clinical trial of dTCApFs, a derivative of a novel human hormone peptide, for the treatment of advanced/metastatic solid tumors StemmerSalomon M. 1 2 BenjaminovOfer 2 3 SilvermanMichael H. 4 SandlerUziel 4 5 PurimOfer 1 2 SenderNaomi 1 MeirChen 1 Oren-ApotekerPnina 4 OhanaJoel 4 DevaryYoram 4 Davidoff Center, Rabin Medical Center, Institute of Oncology, Petah Tikva 49414, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel Department of Radiology, Rabin Medical Center, Petah Tikva 49414, Israel Immune System Key (ISK) Ltd., Jerusalem 9746009, Israel Bioinformatics Department, Lev Academic Center (JCT), Jerusalem 91160, Israel Correspondence to: Professor Salomon M. Stemmer, Davidoff Center, Rabin Medical Center, Institute of Oncology, 39 Jabotinski Street, Petah Tikva 49414, Israel, E-mail: stemmer@post.tau.ac.il; salomon.stemmer@gmail.com 01 2018 15 11 2017 8 1 22 29 31032017 19092017 Copyright: © Stemmer et al. 2018 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The aim of the present phase I first-in-human study was to investigate the safety/efficacy of dTCApFs (a novel hormone peptide that enters cells through the T1/ST2 receptor), in advanced/metastatic solid tumors. The primary objective of this open-label dose-escalation study was to determine the safety profile of dTCApFs. The study enrolled patients (aged ≥18 years) with pathologically confirmed locally advanced/metastatic solid malignancies, who experienced treatment failure or were unable to tolerate previous standard therapy. The study included 17 patients (64% male; median age, 65 years; 47% colorectal cancer, 29% pancreatic cancer). The patients received 1–3 cycles of escalating dTCApFs doses (6–96 mg/m2). The mean number ± standard deviation of treatment cycles/patient was 3.2±1.4; no dose-limiting toxicities were observed up to a dose of 96 mg/m2, and the maximum tolerated dose was not reached. Half-life, maximal plasma concentration, and dTCApFs exposure were found to be linearly correlated with dose. Five patients were treated for ≥3 months (12, 24, 48 mg/m2) and experienced stable disease throughout the treatment period, and 1 experienced pathological complete response. Analysis of serum biomarkers revealed decreased levels of angiogenic factors at dTCApFs concentrations of 12–48 mg/m2, increased levels of anticancer cytokines, and induction of the endoplasmic reticulum (ER) stress biomarker GRP78/BiP. Efficacy and biomarker data suggest that patients whose tumors were T1/ST2-positive exhibited a better response to dTCApFs. In conclusion, dTCApFs was found to be safe/well-tolerated, and potentially efficacious, with linear pharmacokinetics. Consistent with preclinical studies, the mechanism through which dTCApFs exerts anticancer effects appears to involve induction of ER stress, suppression of angiogenesis, and activation of the innate immune response. However, further studies are warranted.

 metastatic cancer phase 1 solid tumor T1/ST2 dTCApFs Introduction

dTCApFs (Nerofe™, Immune System Key Ltd., Jerusalem, Israel) is a novel hormone peptide (14 amino acids) with a demonstrated anticancer activity in the preclinical setting (personal communication with Dr Devary's laboratory, ISK Ltd.). dTCApFs is a derivative of the tumor cell apoptosis factor (TCApF), a 84-amino acid hormone peptide naturally expressed in the thymus, colon and frontal lobe of the brain (1).

Studies in pancreatic, breast and ovarian cell lines investigating the mechanism of action (MOA) through which dTCApFs exerts its anticancer effects, revealed that dTCApFs enters the cells through the T1/ST2 receptor (a member of the Toll/interleukin-1 receptor superfamily), and leads to apoptosis of cancer cells through a novel MOA involving induction of two opposing effects: Induction of structural changes in the Golgi apparatus, loss of Golgi function and induction of endoplasmic reticulum (ER) stress, along with downregulation of the ER stress repair mechanism (personal communication).

We herein report the results of the first-in-human study investigating the safety and efficacy of dTCApFs for the treatment of advanced/metastatic solid tumors.

 Patients and methods <sec> <title>Patients

The present study included adult patients (aged ≥18 years) with pathologically confirmed locally advanced and/or metastatic solid malignancies, who experienced treatment failure or were unable to tolerate previous standard therapy. The key inclusion criteria included evaluable/measurable disease and Eastern Cooperative Oncology Group performance status ≤1. Patients with liver cancer/hepatic metastases were considered eligible if liver function met certain criteria, and patients with brain metastases were considered eligible if radiation therapy was completed ≥4 weeks prior to enrollment and the patient received ≤4 mg/day of dexamethasone. The key exclusion criteria included receiving anticancer treatment 14 days prior to the initiation of the study drug, and a life expectancy of <16 weeks.

 Study design

This was a formal open-label phase I dose-escalation study. The primary objective was to determine the maximum tolerated dose (MTD) and safety profile of dTCApFs. Assessments included drug exposure, adverse events (AEs) graded according to the Common Terminology Criteria for Adverse Events, version 4.0 (https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdf), and characterization of dose-limiting toxicities (DLTs). Other objectives included assessment of serum levels of angiogenic factors following dTCApFs administration, pharmacokinetics (PK) and pharmacodynamics (PD) analyses, as well as assessment of receptor staining and tumor response.

The dose escalation study followed a traditional ‘3+3’ scheme and included doses of 6, 12, 24, 48 and 96 mg/m2 of intravenous (IV) dTCApFs, 3 times/week in consecutive 28-day cycles. The patient's allocation is presented in Fig. 1. In all 3-patient cohorts, there was an interval of 2 weeks between the first dose for the first and second patients, and ≥1 week for the third patient. New dose levels started after a follow-up of ≥28 days for the 3 patients at the previous level. MTD was defined as the highest dose level at which ≥1 of the 3 subjects experienced a DLT during their first cycle of treatment. Patients who did not complete their first cycle of treatment for reasons unrelated to AEs were replaced. In addition, PK parameters, including area under the curve (AUC), maximal plasma concentration (Cmax) and plasma half-life (t1/2) were determined. PK parameters were estimated using non-compartmental models.

The clinical activity of dTCApFs was assessed every 8 weeks by physical examination, computed tomography (CT), or magnetic resonance imaging techniques (for evaluable disease only), using the Response Evaluation Criteria In Solid Tumors v1.1 (https://ctep.cancer.gov/protocoldevelopment/docs/recist_guideline.pdf); where appropriate, informative tumor markers were measured in every cycle.

This study was approved by the Institutional Review Board of Rabin Medical Center and the Ministry of Health of Israel, and was conducted at the Davidoff Center, Rabin Medical Center in accordance with the principles of the Declaration of Helsinki. All the patients signed an informed consent prior to enrollment. The study was registered at ClinicalTrials.gov (NCT01690741).

 Biomarker analysis

Blood samples were collected from patients and placed on ice for 10 min. Serum samples were collected by centrifugation at 1,000 × g for 10 min at 4°C, kept in separate vials at ≤-20°C, and shipped to Immune System Key Ltd. at −20°C, where they were thawed, aliquoted, and stored at ≤-20°C. Repeated freeze-thaw cycles were avoided.

Immunohistochemistry (IHC) staining was performed for T1/ST2 receptor using a full-length anti-ST2 antibody (GenMed, Plymouth, MN, USA). Serum levels of various factors were measured with enzyme-linked immunosorbent assay (ELISA). The measured factors included vascular endothelial growth factor (VEGF), VEGF-D, epidermal growth factor, angiopoietin-1, fibroblast growth factor (FGF)-1, FGF-2, platelet-derived growth factor (PDGF)-AA, PDGF-BB, transforming growth factor (TGF)-β (all using ELISA kits by R&D systems, Abingdon, UK); granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-2, IL-12p70, IL-21 and tumor necrosis factor (TNF)-α (Millipore, Billerica, MA, USA); and glucose-regulated protein 78 (GRP78)/BiP (Enzo, New York, NY, USA).

 Statistical analysis

Descriptive statistics were used for all analyses and were performed with SAS® software, version 9.1 (SAS Institute Inc., Cary, NC, USA). Regression analysis was used to study 2-way correlation between tumor change per month, administered doses of dTCApF, and levels of the ER-stress biomarker (BiP). The statistical significance of the correlation was validated using F-statistics.

 Results <sec> <title>Patients

A total of 39 patients were screened, of whom were 17 enrolled and completed the study. The majority of the patients (64%) were male, and the median age (range) was 65 (51–94) years. Almost half of the patients (47%) had colorectal cancer and 29% had pancreatic cancer. Apart from 1 patient, all other patients had received several lines of anticancer therapy (e.g., chemotherapy, radiotherapy and biological therapy) prior to enrolment (Table I). The patients received 1–3 cycles of escalating dTCApFs doses (6, 12, 24, 48 and 96 mg/m2), as detailed in Fig. 1.

 Safety and tolerability

The mean number of treatment cycles per patient was 3.2±1.4. No DLTs were observed in any patient up to cohort 5. The AEs are summarized in Table II. None were related to the study drug. Hypertension, anemia, vomiting, diarrhea and abdominal pain were the most frequently reported grade 2 AEs, and hypertension was the most frequently reported grade 3 AE. Vomiting was the only grade 4 AE, reported in 1 patient. The majority of the AEs were self-resolving. Overall, treatment with dTCApFs was well-tolerated, with no cumulative toxicity. MTD was not reached.

 PK results

The PK results for the first day of cycles 1 and 2 are summarized in Table III; t1/2, Cmax and AUC0 were found to be linearly correlated with dose. Dose-dependent plasma concentrations of dTCApFs were observed (Fig. 2).

 Efficacy

Of the 17 patients who were treated for ≥3 months (12, 24 and 48 mg/m2), 5 experienced stable disease (SD) throughout the treatment period. Notably, 1 patient was suffering from lower back pain, weakness and referred pain in the left extremity, due to a spinal cord neoplasia compressing the spinal cord (Ki-67, 30%; ST2-positive staining). Treatment with painkillers (e.g., tramadol, oxycodone/naloxone, morphine and pregabalin) was unsuccessful, and the patient used a walker. After 6 months of treatment (12, 24 and 48 mg/m2), the patient's walking improved without the need for any painkiller medication. Surgery was performed after 11 months of treatment. At surgery, no malignancy was observed; however, scar tissue and bleeding were noted, and the histopathological analysis revealed strong presence of natural killer (NK) cells and dendritic cells. A second patient who entered the study with progressive disease after receiving 4 prior lines of chemotherapy treatment, maintained SD through 6 cycles of dTCApFs (6 and 12 mg/m2).

Progression-free survival (PFS) analysis revealed that 6 patients experienced a longer PFS on dTCApFs compared with their prior regimen, and 1 patient had a PFS that was comparable to that on his prior regimen; 1 patient who had not receive prior treatments was able to remain on the study drug for 330 days (Table IV). A regression analysis [robust regression model (2,3)] computing F statistics P-values revealed a statistically significant correlation between changes in tumor size and the administered dTCApFs doses (Fig. 3).

 Biomarker analysis

Treatment with dTCApFs at a dose of 6 mg/m2 led to an increase in serum levels of angiopoietin-1, FGF-1, FGF-2, PDGF-AA, PDGF-BB, VEGF-D, TGF-β and VEGF. At doses of 12–48 mg/m2, a decrease in the serum levels of these factors was observed, and at 96 mg/m2, an increase in all factors, except for VEGF-D, was noted. In addition, the serum levels of all anticancer cytokines, such as GM-CSF, IL2, IL-12p70, IL-21 and TNF-α, increased with dTCApFs administration in all dose levels (Table V).

To assess the MOA of dTCApFs, patients were examined by their T1/ST2 status, as dTCApFs has been shown to enter the cells through this receptor (personal communication). A total of 14 patients underwent CT at 8 weeks and were evaluable for this analysis. We observed that patients whose tumors were T1/ST2-positive (by IHC) remained in the trial longer compared with those whose tumors were T1/ST2-negative (Fig. 4A) and experienced SD on dTCApFs treatment. Therefore, the patient population was re-analyzed (changes in tumor size vs. administered dTCApFs dose), after excluding T1/ST2-positive patients (n=9). In this re-analysis, the correlation coefficient increased from 0.56 to 0.76, and the standard deviation for tumor size decreased from 4.6 to 2.6 (P=0.02). A separate statistically valid regression analysis for the subpopulation of T1/ST2-positive patients could not be performed due to the small sample size (n=4). The serum levels of the GRP78/BiP protein (ER stress biomarker) were also measured prior to the initiation of dTCApFs treatment and after 29 days of treatment. A statistically significant correlation was observed between administered dTCApFs doses and change in serum GRP78/BiP levels (P≤0.05), as well as between changes in tumor size and change in serum GRP78/BiP levels (P≤0.002), suggesting that dTCApFs induced ER stress (Fig. 4B and C). These correlation analyses were then repeated after excluding T1/ST2-negative patients, and an increase in the correlation coefficients (for dTCApFs vs. change in GRP78/BiP levels, from 0.57 to 0.75; for change in GRP78/BiP levels vs. changes in tumor size, from 0.79 to 0.83) were observed, along with a decrease in the standard deviation for GRP78/BiP changes (from 184 to 67 and from 148 to 36, respectively). These changes were statistically significant (P≤0.01).

 Discussion

The aim of the present phase I dose-escalation study was to investigate dTCApFs, a novel hormone peptide, whose activity is driven by its interaction with the T1/ST2 receptor and its anticancer activity is exerted through several MOAs, including a unique MOA involving ER stress induction and downregulation of the ER stress repair mechanism. Intravenous dTCApFs was found to be safe, well-tolerated and potentially efficacious in treating advanced/metastatic solid tumors. Furthermore, the PK examinations revealed that t1/2, Cmax, AUC0 and plasma concentrations of dTCApFs were linearly correlated with dose. In addition, that dTCApFs was found to have anti-angiogenic activity, as well as the ability to induce ER stress and expression of anticancer cytokines.

The present phase I study provides insight into the MOA by which dTCApFs exerts its anticancer effects. dTCApFs enters the cells through the T1/ST2 receptor (personal communication). T1/ST2 is a member of the IL-1 receptor family and IL-33, which regulate the Th1/Th2 immune responses in autoimmune and inflammatory conditions. Lipopolysaccharides have been shown to stimulate T1/ST2 expression in monocytes, muscle cells and splenocytes, both in vitro and in vivo (4). The T1/ST2 receptor is expressed in macrophages, dendritic cells, as well as in mast cells. This receptor is a stable marker of Th2 polarized thymocytes (but not of Th1 polarized thymocytes) and is important in the response of Th2 to viral antigens and allergens (5–7). T1/ST2 has been shown to play an important role in various diseases, including cancer, Alzheimer's disease, inflammatory diseases, trauma, sepsis, cardiovascular diseases and idiopathic pulmonary fibrosis (6–14). Knocking out this receptor in BALB/c mice bearing mammary carcinoma attenuated tumor growth and metastasis. In these knockout mice (compared with wild-type mice), the serum levels of IL-17, interferon-γ and TNF-α increased, along with higher ex vivo cytotoxic activity of splenocytes, NK cells and CD8+ T cells (1). In the present study, dTCApFs treatment led to increased serum levels of anticancer cytokines (e.g., GM-CSF, IL-12p70, IL-2, IL-21 and TNF-α), likely due to the downregulation of the T1/ST2 receptor. In addition, a correlation between the antitumor activity of dTCApFs and T1/ST2 expression status in the tumors was observed. A direct correlation was found between T1/ST2 positivity, tumor size changes and induction of ER stress. These findings are consistent with preclinical studies, where treating ST2 gene knockout OV-90 cells with dTCApFs did not result in ER stress. Taken together, these observations suggest that the T1/ST2 receptor may serve as a biomarker to select T1/ST2-positive patients who are more likely to respond to dTCApFs. Additionally, the biomarker analysis revealed that dTCApFs treatment increased the levels of IL-21 and IL12p70, which are known activators of NK cells (15,16), as well as the levels of GM-CSF and IL-2, which are known activators of dendritic cells (17,18). Furthermore, histopathological analysis of a post-treatment surgical specimen from a patient who achieved a complete response revealed strong presence of NK and dendritic cells. These findings suggest that dTCApFs may activate the innate immune response, consistent with prior studies showing such response with ST2 activation (19,20). Drugs with MOAs involving ST2 activation are currently being investigated (21,22). dTCApFs was also found to have broad anti-angiogenic properties (it reduced the expression of multiple angiogenic factors at levels of 12–48 mg/m2). Targeting angiogenesis is a well-established MOA in anticancer drugs, with commercially available and investigational drugs targeting factors such as VEGF and FGF receptors (5,23–25). It should be noted that, despite an observed increase in the levels of angiogenic factors with dTCApFs treatment at the highest investigated dose (96 mg/m2), the cytotoxic activity of dTCApFs was, in fact, enhanced at this dose level, possibly due to another MOA of dTCApFs.

Notably, the findings of dTCApFs-induced ER stress are consistent with our preclinical studies showing a novel mechanism involving two opposing effects of dTCApFs that together result in apoptosis: ER stress induction, and downregulation of the ER stress repair mechanism. Specifically, dTCApFs molecules enter the cells through the ST2 receptor. Subsequently, they bind to the sST2 soluble T1/ST2 receptor, enter the Golgi apparatus, and induce structural changes that lead to destruction of the Golgi apparatus and loss of Golgi function. This, in turn, leads to accumulation of proteins in the ER, resulting in ER stress. dTCApFs also downregulates sXBP1 and, thus, inhibits the ER stress repair mechanism, leading to apoptosis. Interestingly, over the last decade, the interaction between ER stress and tissue vascularization has been intensively investigated and a clear interaction between the stress-response mechanism and VEGF was observed in cancer, diabetic retinopathy, atherosclerosis and ischaemic renal disease (26). GRP78/BiP is as an ER stress marker, and its upregulation following anti-angiogenic therapy has been demonstrated in multiple studies. For example, Han et al, demonstrated that sunitinib treatment, which inhibits PDGF and vascular VEGFR receptors, induced hypoxia in Caki-1 xenografts, that was followed by elevated expression of GRP78/BiP in the treated group compared with the control group (27). It may be hypothesized that dTCApFS interrupts angiogenesis, thereby causing accumulation of unfolded proteins in the ER of the cancer cells, resulting in ER stress, leading to apoptosis.

In conclusion, treatment with intravenous dTCApFs (6–96 mg/m2, 3 times/week, in consecutive 28-day cycles) in locally advanced or metastatic solid tumors was found to be safe and well-tolerated, with a dose-dependent, linear PK. dTCApFs suppressed angiogenic factors, induced anticancer cytokine production and ER stress, which likely led to the clinical outcome observed in some of our patients. Positive T1/ST2 staining may serve as a predictive marker for response to dTCApFs. Further studies on the efficacy of dTCApFs in advanced malignancies expressing high levels of T1/ST2 are warranted.

 Acknowledgements

The present study was supported by ISK and Israel Chief Scientist grants (grant no. 54811). Silverman MH, Sandler U, Oren-Apoteker P, Ohana J and Devary Y are employed by ISK.

 References SandlerUDevaryOBraitbardOOhanaJKassGRubinsteinAMFriedmanZYDevaryYNEROFE-a novel human hormone-peptide with anti-cancer activityJ Exp Ther Oncol8327339201021222365 MarazziAAlgorithms, routines and S functions for robust statistics: The FORTRAN library ROBETH with an interface to S-PLUSChapman and HallNew York City, NY1993 FoxJApplied regression analysis, linear models, and related methodsSage Publications, Inc.London, England1997 SaccaniSPolentaruttiNPenton-RolGSimsJEMantovaniADivergent effects of LPS on expression of IL-1 receptor family members in mononuclear phagocytes in vitro and in vivoCytokine10773780199810.1006/cyto.1998.03599811530 GutheilJCCampbellTNPiercePRWatkinsJDHuseWDBodkinDJChereshDATargeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3Clin Cancer Res630563061200010955784 LuDPZhouXYYaoLTLiuCGMaWJinFWuYFSerum soluble ST2 is associated with ER-positive breast cancerBMC Cancer14198201410.1186/1471-2407-14-19824636276 O'DonnellCMahmoudAKeaneJMurphyCWhiteDCareySO'RiordainMBennettMWBrintEHoustonAAn antitumorigenic role for the IL-33 receptor, ST2L, in colon cancerBr J Cancer1143743201610.1038/bjc.2015.43326679377 LambrechtBNDe VeermanMCoyleAJGutierrez-RamosJCThielemansKPauwelsRAMyeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammationJ Clin Invest106551559200010.1172/JCI810710953030 WalzlGMatthewsSKendallSGutierrez-RamosJCCoyleAJOpenshawPJHussellTInhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathologyJ Exp Med193785792200110.1084/jem.193.7.78511283151 CoyleAJLloydCTianJNguyenTErikksonCWangLOttosonPPerssonPDelaneyTLeharSCrucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responsesJ Exp Med190895902199910.1084/jem.190.7.89510510079 MeiselCBonhagenKLöhningMCoyleAJGutierrez-RamosJCRadbruchAKamradtTRegulation and function of T1/ST2 expression on CD4+ T cells: Induction of type 2 cytokine production by T1/ST2 cross-linkingJ Immunol16631433150200110.4049/jimmunol.166.5.314311207266 XuDChanWLLeungBPHuangFPWheelerRPiedrafitaDRobinsonJHLiewFYSelective expression of a stable cell surface molecule on type 2 but not type 1 helper T cellsJ Exp Med187787794199810.1084/jem.187.5.7879480988 TownsendMJFallonPGMatthewsDJJolinHEMcKenzieANT1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responsesJ Exp Med19110691076200010.1084/jem.191.6.106910727469 XiongZThangavelRKempurajDYangEZaheerSZaheerAAlzheimer's disease: Evidence for the expression of interleukin-33 and its receptor ST2 in the brainJ Alzheimers Dis40297308201424413615 Van ElssenCHVanderlochtJFringsPWSenden-GijsbersBLSchnijderbergMCvan GelderMMeekBLibonCFerlazzoGGermeraadWTBosGMKlebsiella pneumoniae-triggered DC recruit human NK cells in a CCR5-dependent manner leading to increased CCL19-responsiveness and activation of NK cellsEur J Immunol4031383149201010.1002/eji.20104049620865789 FrederiksenKSLundsgaardDFreemanJAHughesSDHolmTLSkrumsagerBKPetriAHansenLTMcArthurGADavisIDSkakKIL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinomaCancer Immunol Immunother5714391449200810.1007/s00262-008-0479-418286285 WuestSCEdwanJHMartinJFHanSPerryJSCartagenaCMMatsuuraEMaricDWaldmannTABielekovaBA role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapyNat Med17604609201110.1038/nm.236521532597 van de LaarLCofferPJWoltmanAMRegulation of dendritic cell development by GM-CSF: Molecular control and implications for immune homeostasis and therapyBlood11933833393201210.1182/blood-2011-11-37013022323450 RankMAKobayashiTKozakiHBartemesKRSquillaceDLKitaHIL-33-activated dendritic cells induce an atypical TH2-type responseJ Allergy Clin Immunol12310471054200910.1016/j.jaci.2008.12.16919361843 NabekuraTGirardJPLanierLLIL-33 receptor ST2 amplifies the expansion of NK cells and enhances host defense during mouse cytomegalovirus infectionJ Immunol19459485952201510.4049/jimmunol.150042425926677 ClinicalTrials.govDescription of a trial investigating Interleukin-12 in ovarian epithelial cancer or primary peritoneal cancerhttps://clinicaltrials.gov/ct2/show/NCT00016289?term=IL12p70&rank=7January112017 ClinicalTrials.govDescription of the recombinant interleukin-21 in metastatic melanoma and kidney cancerhttps://clinicaltrials.gov/ct2/show/NCT00095108?term=IL-21&rank=7January112017 VasudevNSReynoldsARAnti-angiogenic therapy for cancer: Current progress, unresolved questions and future directionsAngiogenesis17471494201410.1007/s10456-014-9420-y24482243 BoehmTFolkmanJBrowderTO'ReillyMSAntiangiogenic therapy of experimental cancer does not induce acquired drug resistanceNature390404407199710.1038/371269389480 JainRKAntiangiogenic therapy for cancer: Current and emerging conceptsOncology (Williston Park)194 Suppl 3S7S162005 TahergorabiZKhazaeiMImbalance of angiogenesis in diabetic complications: The mechanismsInt J Prev Med3827838201210.4103/2008-7802.10485323272281 HanKSLiNRavenPAFazliLFreesSEttingerSParkKCHongSJGleaveMESoAIInhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2α pathwayOncotarget63481834830201526472187

Schematic representation of patient randomization and allocation.

Serum concentrations of dTCApFs over time by dose group. Error bars represent standard deviation.

Correlation between changes in tumor size and the administered dTCApFs dose. A total of 14 patients who underwent computed tomography examination at 8 weeks were included in the analysis.

(A) Number of days in trial for patients according to T1/ST2 expression on immunohistochemistry. (B) Correlation between change in serum levels of the endoplasmic reticulum (ER) stress marker BiP and dTCApFs dose. (C) Correlation between change in serum levels of BiP and change in tumor size. A total of 14 patients who underwent computed tomography examination at 8 weeks were included in the analysis.

Patient demographics and baseline characteristics.

dTCApFs dose, mg/m2
Characteristics 6 (n=3) 12 (n=3) 24 (n=3) 48 (n=3) 96 (n=5)
Age, years
  Median (range) 63 (62–77) 61 (58–62) 65 (57–67) 72 (51–94) 64 (55–77)
  Mean (SE) 68 (5) 67 (4) 67 (2) 72 (8) 64 (9)
  Sex, n (male/female) 3/0 2/1 1/2 2/1 3/2
Tumor type, n
  Colorectal 3 2 0 2 1
  Pancreatic 0 0 1 0 4
  Othera 0 1 2 1 0
Prior therapies, n
  Chemotherapy 3 4 4 1 3
  Radiotherapy 1 2 1 1 0
  Surgery 2 2 1 1 2
  Treatment with biological agents 0 0 1 0 0
  Treatment with small molecules, such as TKIs. 0 0 0 1 0

Includes neoplasms in the small intestine, lung, liver, and spinal cord. SE, standard error; TKIs, tyrosine kinase inhibitors.

Summary of adverse events by dTCApFs dose group.

dTCApFs dose, mg/m2
Adverse events 6 (n=3) 12 (n=3) 24 (n=3) 48 (n=3) 96 (n=5)
Grade 1
  Blood disorders
    Anemia 3 0 0 0 0
    Increased INR 0 0 0 1 0
  GI disorders
    Abdominal pain 0 1 2 0 0
    Bowel obstruction 1 0 0 0 0
    Diarrhea 0 2 0 0 2
    GI hemorrhage 1 0 0 0 0
    Vomiting 2 0 0 0 1
  General disorders
    Dehydration 0 0 0 0 1
    Fatigue 0 1 0 1 0
    Hypertension 3 1 1 0 1
  Nervous system disorders
    Neuropathy 0 1 1 0 0
Grade 2
  Pain
    Pain, leg 0 2 0 0 0
    Pain, upper back 0 0 0 0 1
  Respiratory system disorders
    Cough 0 1 0 0 0
  Skin disorders
    Pruritus 0 0 0 0 1
    Urticaria 0 0 0 0 1
  Hepatic and urinary disorders
    ALT increase 0 0 0 0 1
    AST increase 0 0 0 0 1
    Bilirubin increase 0 0 0 1 1
    Liver dysfunction 0 0 0 0 1
    Urinary tract infection 0 1 0 0 0
Grade 3
  Blood disorders
    Increased INR 0 0 0 1 0
  General disorders
    Hypertension 2 1 1 0 2
  Hepatic and urinary disorders
    Bilirubin increase 0 0 0 1 1
  GI disorders
    Bowel obstruction 1 0 0 0 0
    Diarrhea 0 1 0 0 1
    GI hemorrhage 1 0 0 0 0
Grade 4
  GI disorders
    Vomiting 0 0 0 0 1

ALT, alanine transaminase; AST, aspartate aminotransferase; GI, gastrointestinal; INR, international normalized ratio.

Pharmacokinetics of dTCApFs on the first day of cycles 1 and 2 (each cycle was 28 days).

Cycle 1, day 1 Cycle 2, day 1
dTCApFs dose, mg/m2 6 (n=3) 12 (n=4) 24 (n=4) 48 (n=4) 96 (n=3) 6 (n=3) 12 (n=4) 24 (n=4) 48 (n=4) 96 (n=3)
AUC0, ng·h/ml 3,813 12,905 49,630 79,935 206,742 9,719 11,452 57,069 100,093 294,682
Cmax, ng/ml 1,209 6,048 14,609 18,267 32,964 1,536 6,048 14,609 22,113 32,016
t1/2, h 2.3 2.1 3.2 4.9 6.0 2.8 2.0 3.7 4.6 8.5

AUC, area under the curve; Cmax, maximal plasma concentration; t1/2, plasma half-life.

PFS on the last regimen before enrolling the study and on dTCApFs.

Patient no. PFS on the last regimen pre-enrollment, days PFS on dTCApFs, days
  1   480   53
  2   134   25
  3   110   170
  4       0 330
  5     52   51
  6   384 110
  7     54   90
  8     80   52
  9   375   60
10 1,800   14
11     41   52
12     42   50
13     96   42
14   365   40
15       1   80
16   105   45
17   564   41

Rows with bold print represent patients who experienced PFS on dTCApFs, which was comparable with or exceeded that of their last regimen pre-enrollment. PFS, progression-free survival.

Mean change (%) in serum levels of angiogenic factors and cytokines pre- to post- treatment with dTCApFs.

dTCApFs dose, mg/m2
Factors 6 (n=3) 12 (n=3) 24 (n=3) 48 (n=3) 96 (n=5)
Angiogenic factors
  Angiopoietin-1 +960 −80 −77 −50 +70
  FGF-1 +120 −62 −20 −27 +457
  FGF-2 +199 −74 −34 −13 +44
  PDGF-AA +1,379 −92 −79 −73 +57
  PDGF-BB +2,271 −95 −82 −78 +185
  VEGF-A +265 −47 −62 −72 −2
  TGF-β1 +18 −80 −59 −20 No data
  VEGF-D +117 −40 −54 −63 +3
Cytokines
  GM-CSF +2,173 −97 +11 +5,613 +974
  IL-12-p70 +469 −76 +83 +477 +332
  IL-2 No data −100 No data +242 +577
  IL-21 +100 −61 +84 +1,326 +29
  TNF-α +4 −5 +31 +74 +97

FGF, fibroblast growth factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; PDGF, platelet-derived growth factor; TGF, transforming growth factor; VEGF, vascular endothelial growth factor; TNF, tumor necrosis factor.